• Discovering & developing proprietary prodrugs

    Our products have improved properties over approved drugs and address unmet medical needs in large, established markets.

  • Creating a diverse pipeline of prodrug therapeutics

    We employ our LAT™ (Ligand Activated Therapy) platform technology to improve the attributes of approved drugs.

  • Decades of experience in devising elegant solutions

    KemPharm® continues to implement its LAT™ platform technology to create prodrugs that are new molecules by chemically attaching ligand(s) to the parent drug.

Our Value Proposition

KemPharm® believes that its LAT™ Platform technology offers potential benefits to improve drug properties by developing prodrugs that are new molecules with improved attributes over FDA-approved drugs, such as enhanced bioavailability, extended duration of action, increased safety, and reduced susceptibility to abuse.

Learn More

KemPharm’s pipeline consists of multiple programs targeting opportunities in ADHD, pain, and CNS indications.

We employ our LAT™ (Ligand Activated Therapy) platform technology to improve the attributes of approved drugs.

Learn more about LAT™

March 20, 2018

Featured Publication

Positive Topline Results from KP415 PK Study in Children/Adolescents With ADHD

Results Suggest that Data from Single Classroom-style Efficacy Study May Be Applicable Across Pediatric, Adolescent and Adult ADHD Patient Populations Coralville, IA – March 20, 2018 – KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that topline results from its […]

keep reading

KemPharm® Company Overview
KemPharm® Company Culture
  • KemPharm Reports Fourth Quarter and Year End 2017 Results

  • KemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results

  • Positive Topline Results from KP415 PK Study in Children/Adolescents With ADHD